Mental Health · Perinatal
PHQ-9 Perinatal Depression Screen
The Patient Health Questionnaire-9 — the most widely-used self-report depression screen, mapped directly to the DSM-5 criteria for major depressive disorder. Endorsed for perinatal screening by ACOG (CPG #4, 2023) and USPSTF (2023, Grade B). 9 questions, 5 minutes, with plain-English interpretation.
Last reviewed 25 May 2026
PHQ-9 — perinatal depression screen
Over the last 2 weeks, how often have you been bothered by…
Each item asks how often over the past 2 weeks. Answer honestly — there are no wrong answers. ACOG (2023) recommends this screen at least once during pregnancy and at the postpartum visit; AAP additionally recommends at 1-, 2-, 4-, and 6-month well-child visits.
Answer all 9 questions to see your total score.
Introduction
The PHQ-9 is a nine-item self-report depression screen developed by Kroenke, Spitzer, and Williams in 2001 (J Gen Intern Med). Each item maps directly onto one of the DSM-5 criteria for Major Depressive Disorder. It is the most widely-used depression screen in primary care worldwide, with translations validated in over 30 languages.
In perinatal care it is endorsed by ACOG (Clinical Practice Guideline #4, June 2023) as one of two preferred screening instruments (the other being the Edinburgh Postnatal Depression Scale) and was specifically cited by the US Preventive Services Task Force as a Grade B-recommended tool for screening for depression in pregnancy and the postpartum period (USPSTF 2023, JAMA).
Background — what the PHQ-9 measures
The nine items map onto the nine DSM-5 criteria for major depressive disorder:
- Anhedonia (loss of interest or pleasure)
- Depressed mood
- Sleep disturbance
- Fatigue / low energy
- Appetite change
- Worthlessness / guilt
- Concentration difficulty
- Psychomotor change
- Thoughts of self-harm / suicide
Each item is scored 0 (not at all), 1 (several days), 2 (more than half the days), or 3 (nearly every day). Total ranges 0-27. A DSM diagnosis of major depressive disorder requires five or more of the nine criteria including either anhedonia or depressed mood — which is functionally equivalent to a total score around 10 in most validation cohorts.
How to use this screen
- Read each item.
- Choose the response that best matches how often you’ve been bothered by that problem over the past 2 weeks.
- Be honest — there are no wrong answers and the result is for your information.
- Pay particular attention to question 9 — any positive answer triggers a same-day safety check regardless of total.
How to interpret your result
- 0-4 — Minimal. Responses don’t suggest clinically significant depression right now.
- 5-9 — Mild. Symptoms present. Watchful waiting, lifestyle measures, and a supportive conversation usually first steps.
- 10-14 — Moderate. Symptoms warrant a clinical conversation. Talking therapies (CBT, IPT) are usually first-line; medication considered depending on functional impact.
- 15-19 — Moderately severe. Symptoms significantly affecting daily functioning. Combined psychotherapy + antidepressant typical.
- 20-27 — Severe. Immediate clinical contact recommended; same-day perinatal mental-health referral appropriate.
- Question 9 > 0 at any total — Same-day safety assessment. Self-harm thoughts are common but always taken seriously.
What to do if you score positive
A positive screen is the START of a conversation, not a label. The next step is a clinical interview with your obstetric provider, midwife, GP, health visitor, or perinatal mental-health team to confirm whether the symptoms meet diagnostic criteria and to agree on a treatment plan.
Effective treatments exist and are available in pregnancy and breastfeeding:
- Talking therapy — cognitive-behavioural therapy (CBT), interpersonal therapy (IPT), behavioural activation. Available via IAPT in England, primary-care psychology in the US, and perinatal mental-health services elsewhere.
- Antidepressant medication — many SSRIs are pregnancy- and lactation-compatible; sertraline is the most-studied in breastfeeding. Decision is shared between you, your obstetric team, and (where indicated) a perinatal psychiatrist.
- Combination treatment — psychotherapy + medication, the most effective approach for moderate-to-severe depression.
- Peer support — Postpartum Support International (US), PANDAS (UK), antenatal/postnatal peer groups.
What this screen does NOT do
- It is not a diagnosis. Diagnosis requires a clinical interview confirming DSM-5 / ICD-11 criteria.
- It does not screen for postpartum psychosis — a separate rare but emergency condition (auditory hallucinations, severe confusion, paranoid thoughts about the baby) needing same-day psychiatric assessment.
- It does not screen for postpartum OCD, PTSD, or bipolar disorder — those have their own validated tools and presentations.
- It is a snapshot — feelings can shift; if symptoms persist or worsen, re-screen.
Limitations
- Cultural differences in symptom presentation can affect score validity.
- Physical symptoms (sleep, appetite, fatigue) overlap with normal pregnancy and postpartum — some clinicians prefer the EPDS in late pregnancy and the first 6 weeks postpartum for this reason.
- The screen is short by design — clinical interview is the gold standard.
- Some women under-report symptoms due to stigma or fear of consequences (e.g. social services); a positive screen is taken seriously, and clinicians are not in the business of removing babies from mothers with depression.
Sources
- Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-13.
- Manea L, Gilbody S, McMillan D. Optimal cut-off score for diagnosing depression with the PHQ-9: a meta-analysis. CMAJ 2012;184:E191-6.
- American College of Obstetricians and Gynecologists. Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum (Clinical Practice Guideline #4). Obstet Gynecol 2023.
- US Preventive Services Task Force. Screening for Depression and Suicide Risk in Adults: USPSTF Recommendation Statement. JAMA 2023;329:2057-67.
- Sidebottom AC, et al. Validation of the Patient Health Questionnaire (PHQ-9) for prenatal depression screening. Arch Womens Ment Health 2012;15:367-74.
- National Institute for Health and Care Excellence. Antenatal and postnatal mental health: clinical management and service guidance (CG192). 2014, updated 2020.
Frequently asked questions
What's the difference between the EPDS and the PHQ-9?
Both screen for perinatal depression. The Edinburgh Postnatal Depression Scale (EPDS) was developed in 1987 specifically for the postnatal period and deliberately excludes physical symptoms (sleep loss, fatigue, low energy) because those are nearly universal in new mothers and cause false positives. The PHQ-9 is the most widely-used general depression screen, mapped directly to the nine DSM-5 criteria for Major Depressive Disorder. ACOG CPG #4 (2023) recommends either is acceptable in pregnancy; the PHQ-9 has wider validation across general primary-care settings and is the USPSTF-endorsed instrument for perinatal depression screening.
What does my score mean?
0-4 minimal depression — your responses don't suggest clinically significant depression right now. 5-9 mild — symptoms present; watchful waiting + lifestyle measures usually first steps. 10-14 moderate — symptoms warrant clinical conversation; psychotherapy and/or medication considered. 15-19 moderately severe — treatment recommended; combination of psychotherapy + antidepressant typical. 20-27 severe — immediate clinical contact / same-day mental-health referral. A perinatal-specific cutoff of ≥10 has sensitivity 84 % and specificity 81 % for major depressive disorder.
Why is question 9 so important?
Question 9 asks about thoughts of being better off dead or hurting yourself. Any positive answer — even 'several days' — warrants a same-day clinical contact, regardless of your total score. Suicidal ideation in pregnancy and postpartum is more common than people realise (3-7 % of perinatal women have any suicidal thoughts) and is the second-leading cause of maternal mortality in the year after birth in many high-income countries (UK MBRRACE 2023, US PMP 2024). Acting on it is rare; talking about it usually helps.
I screened positive — what happens next?
Confirmed major depressive disorder is treatable in pregnancy and breastfeeding. First-line: structured psychotherapy (CBT, interpersonal therapy, behavioural activation), often delivered by IAPT in the UK or perinatal mental-health teams elsewhere. Medication: SSRIs (sertraline preferred in lactation; many pregnancy-compatible) are appropriate where functional impact is significant. Combined treatment is most effective for moderate-severe depression. Untreated perinatal depression has worse outcomes for both mother and baby than treated — the safer choice is treatment, not avoidance.
Are antidepressants safe in pregnancy and breastfeeding?
Most SSRIs and SNRIs have decades of pregnancy and lactation data. Sertraline is the most-studied antidepressant in breastfeeding and is generally preferred. Citalopram, escitalopram, and fluoxetine are also commonly used. Paroxetine is generally avoided in the first trimester (small association with cardiac malformations). Untreated maternal depression carries known risks for both mother (suicidality, postpartum complications) and baby (preterm birth, low birth weight, developmental impact). The decision is shared with a perinatal psychiatrist or your obstetric/primary care provider.
Should I screen myself if I'm not sure I'm depressed?
Yes — that's exactly what screens are for. Many people who later meet criteria for depression don't initially recognise their mood as 'depression'; it can feel like exhaustion, irritability, disconnection, or numbness. The 5-minute screen costs nothing and the result either reassures you or prompts a conversation. ACOG, USPSTF, NICE, and AAP all recommend universal screening — meaning every pregnant and postpartum person, not just those identified as 'high risk'.
Is the PHQ-9 reliable in pregnancy?
Yes — validated across multiple perinatal cohorts (Sidebottom 2012, Smith 2010, Yawn 2015). The 10-point cutoff has sensitivity 84 % and specificity 81 % for major depressive disorder in pregnancy and postpartum. Some pregnancy-specific items (sleep, appetite) score higher than baseline, but the algorithm is robust enough that the overall cutoff remains valid. ACOG 2023 endorses it alongside the EPDS.
When should I be screened?
ACOG CPG #4 (2023) recommends screening at least once during pregnancy AND at the comprehensive postpartum visit (4-12 weeks post-birth). AAP additionally recommends maternal screening at 1-, 2-, 4-, and 6-month well-child visits — recognising that postpartum depression most commonly presents in the months after birth. NICE recommends antenatal and postnatal screening. If your provider doesn't offer it, you can complete the screen yourself and bring the result to your next appointment.